AKT1 and acute lymphoblastic leukemia: The therapeutic potential of TCN for T-ALL was reported by Evangelisti et al [22], who showed that TCN, a highly specific Akt inhibitor, induced autophagy and synergized with vincristine, a chemotherapeutic drug for T-ALL patients.